Wen Si

1.1k citations
44 papers · 736 indexed · h-index 16
  • Nephrology top 5%
    • Chronic Kidney Disease and Diabetes 3
    • Gout, Hyperuricemia, Uric Acid 3
    • Cancer-related molecular mechanisms research 5
    • MicroRNA in disease regulation 3
    • Breast Cancer Treatment Studies 3
    • Inflammasome and immune disorders 5
    • Heme Oxygenase-1 and Carbon Monoxide 3
    • Cytokine Signaling Pathways and Interactions 2

Wen Si

42 papers receiving 730 citations

Peers

Wen Si
Comparison fields: 5 of 107
  • Nephrology 155
  • Cancer Research 147
  • Immunology 126
  • Molecular Biology 389
  • Oncology 122
Replace Gaiqin Pei with:
Gaiqin Pei China
Zhengzhe Li China
Yu-Juei Hsu Taiwan
Naijun Miao China
Silke Zimmermann Germany
Jingti Deng China
Tongyu Zhu China
Laura Márquez‐Expósito Spain
Sanae Teshigawara Japan
Wen Si relative to Gaiqin Pei China Gaiqin Pei's profile →
Citations per field
00.5×10×15×
Gaiqin Pei · 1×
Citations per year

Countries citing papers authored by Wen Si

Since Specialization
Citations

This map shows the geographic impact of Wen Si's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wen Si with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wen Si more than expected).

Fields of papers citing papers by Wen Si

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wen Si. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wen Si. The network helps show where Wen Si may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Wen Si, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Wen Si Line = papers co-authored together Wen Si links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20251
2 20241
3 202423
4 20241
5 20231
6 20234
7 20237
8 20234
9 20232
10 202219
11 202020
12 202037
13 202058
14 202036
15 2019145
16 201526
17 20159
18 201416
19 201016
20 200811

About Wen Si

Wen Si is a scholar working on Nephrology, Cancer Research and Transplantation, having authored 44 papers that have together received 736 indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (5 papers), Inflammasome and immune disorders (5 papers), MicroRNA in disease regulation (3 papers), Chronic Kidney Disease and Diabetes (3 papers), Heme Oxygenase-1 and Carbon Monoxide (3 papers), Breast Cancer Treatment Studies (3 papers), Gout, Hyperuricemia, Uric Acid (3 papers) and Cytokine Signaling Pathways and Interactions (2 papers). The work is most often cited by research in Nephrology (155 citations), Cancer Research (147 citations) and Immunology (126 citations). Wen Si has collaborated with scholars based in China, Hong Kong and United States. Frequent co-authors include Qiuling Fan, Lulu Li, Hong Liu, Shuguang Yuan, Junlan Yang, Xuejing Zhu, Yanyun Zhu, Youliang Wang, Xin Li and Fuyou Liu. Their work appears in journals such as Medicine, Diabetes Metabolic Syndrome and Obesity, Tumor Biology, Organic Chemistry Frontiers and Cell Death Discovery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026